drugset / Trial / NCT06125197
Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer
Phase 1
Active not recruiting
22 enrolled
TILT Biotherapeutics Ltd.
Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open label, Phase 1, dose escalation trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab in patients with immune checkpoint inhibitor refractory non-small cell lung cancer.
Timeline
- Start
- 2024-07-23
- Primary completion
- 2026-01-30
- Completion
- 2026-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | igrelimogene litadenorepvec | Unknown | — | — |